ORMP Stock Price, Oramed Pharmaceuticals Quote, Chart

Market Summary

USD2.20-0.13

Market Closed

-5.58%

ORMP Stock Price

View Fullscreen

ORMP RSI Chart

ORMP Valuation

Market Cap

89.1M

Price/Earnings (Trailing)

16.46

Price/Sales (Trailing)

66.52

EV/EBITDA

-10.07

Price/Free Cashflow

-8.45

ORMP Price/Sales (Trailing)

ORMP Profitability

Operating Margin

98.66%

EBT Margin

-760.00%

Return on Equity

3.33%

Return on Assets

2.46%

Free Cashflow Yield

-11.83%

ORMP Fundamentals

ORMP Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ORMP Earnings

Earnings (TTM)

5.4M

Earnings Growth (Yr)

209.7%

Earnings Growth (Qtr)

517.26%

Breaking Down ORMP Revenue

Last 7 days

-14.7%

Last 30 days

-22.3%

Last 90 days

-1.3%

Trailing 12 Months

-3.5%

How does ORMP drawdown profile look like?

ORMP Financial Health

Current Ratio

3.06

ORMP Investor Care

Shares Dilution (1Y)

1.85%

Diluted EPS (TTM)

0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.8M	4.9M	3.1M	1.3M
2022	2.8M	2.5M	2.5M	1.7M
2021	2.9M	2.9M	2.7M	2.8M
2020	2.7M	2.7M	2.7M	2.7M
2019	2.6M	2.6M	2.7M	2.7M
2018	2.5M	2.5M	2.4M	2.5M
2017	1.5M	2.0M	2.5M	2.5M
2016	0	0	641.0K	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oramed Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	reznick yehuda	acquired	-	-	29,800	-
Jan 30, 2024	aghion daniel	acquired	-	-	3,750	-
Jan 04, 2024	silberman david	acquired	-	-	136,500	chief financial officer
Jan 04, 2024	aghion daniel	acquired	-	-	35,070	-
Jan 04, 2024	shapiro benjamin	acquired	-	-	35,070	-
Jan 04, 2024	sank leonard	acquired	-	-	39,325	-
Jan 04, 2024	kidron nadav	acquired	-	-	329,000	president and ceo
Jan 04, 2024	kidron miriam	acquired	-	-	295,500	chief scientific officer
Jan 04, 2024	hexter joshua	acquired	-	-	180,500	coo & cbo
Jan 04, 2024	mayer arie	acquired	-	-	39,325	-

Which funds bought or sold ORMP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-4.2	5,799	33,288	-%
Apr 11, 2024	CITY HOLDING CO	unchanged	-	663	3,124	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-197	1,518	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-3.59	-10,405	60,522	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-400,943	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-45,000	-	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-232,000	-	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-28.07	-17,000	30,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	775	192,167	220,647	-%
Feb 14, 2024	Murchinson Ltd.	new	-	2,425,500	2,425,500	0.42%

Are Funds Buying or Selling ORMP?

Are funds buying ORMP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORMP

No. of Funds

Unveiling Oramed Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	kidron nadav	5.7%	2,343,919	SC 13D
Sep 02, 2021	kidron nadav	4.1%	1,343,446	SC 13D/A
Feb 09, 2021	slager david mark	5.04%	1,344,123	SC 13G/A
Feb 14, 2020	altium capital management lp	4.99%	972,000	SC 13G/A
Feb 11, 2020	slager david mark	7.4%	1,316,323	SC 13G
Jan 21, 2020	sabby management, llc	4.99%	885,015	SC 13G/A

Recent SEC filings of Oramed Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	4	Insider Trading
Apr 02, 2024	3	Insider Trading
Mar 22, 2024	SC 13D	13D - Major Acquisition
Mar 19, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	424B5	Prospectus Filed
Mar 06, 2024	10-K	Annual Report
Feb 20, 2024	8-K	Current Report
Jan 30, 2024	4	Insider Trading

Peers (Alternatives to Oramed Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.83	14.44	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.02	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.43	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Oramed Pharmaceuticals Inc News

Latest updates

Oramed Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-100.0%	-	1,239,000	2,478,000	1,597,000	158,000	682,000	350,000	544,000	904,000	674,000	682,000	678,000	674,000	681,000	666,000	665,000	904,000	674,000	681,000	681,000	674,000
S&GA Expenses	1414.0%	8,712,000	-663,000	192,000	-	12,378,000	463,000	380,000	590,000	898,000	585,000	172,000	1,050,000	1,926,000	1,297,000	-	1,664,000	-	727,000	730,000	1,030,000	1,391,000
R&D Expenses	84.5%	1,766,000	957,000	1,821,000	4,427,000	9,037,000	5,347,000	9,179,000	5,836,000	9,037,000	6,410,000	6,086,000	8,872,000	3,198,000	5,502,000	6,168,000	3,869,000	6,889,000	5,774,000	2,968,000	1,925,000	3,320,000
EBITDA Margin	-Infinity%	-5.93	-	-	-	-9.76	-9.91	-	-	-6.52	-6.52	-	-6.52	-6.53	-6.53	-4.88	-4.88	-4.25	-4.25	-4.25	-4.06	-4.94
Interest Expenses	-100.0%	-	826,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	2,558,000	308,000	-	100,000	617,000	122,000	128,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	504.9%	13,296,000	-3,284,000	-	-	-13,043,000	-7,153,000	-	-	-	-	-7,536,000	-	-	-5,625,000	-	-4,608,000	-	-	-2,996,000	-2,284,000	-3,688,000
EBT Margin	1.3%	-7.60	-7.70	-1.71	-2.51	-3.26	-4.64	-4.66	-4.11	-4.14	-4.18	-4.21	-4.25	-4.29	-3.95	-3.96	-3.94	-	-	-	-	-
Net Income	517.3%	13,444,000	-3,222,000	-1,194,000	-3,611,000	-12,255,000	-7,060,000	-10,533,000	-10,708,000	-12,255,000	-8,098,000	-7,536,000	-10,413,500	-3,909,000	-5,207,000	-6,063,000	-4,608,000	-7,324,000	-5,570,000	-2,996,000	-2,284,000	-3,688,000
Net Income Margin	180.2%	4.04	-5.04	-3.59	-7.30	-11.49	-16.35	-16.83	-13.76	-13.78	-10.87	-9.90	-9.45	-7.37	-7.96	-8.10	-7.01	-	-	-	-	-
Free Cashflow	-95.7%	-1,421,000	-726,000	-2,654,000	-5,748,000	-8,370,000	-2,362,000	-8,510,000	-9,172,000	-11,131,000	-7,214,000	-9,460,000	-9,460,000	-3,709,000	-3,709,000	-3,709,000	-1,164,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.5%	221	231	156	160	162	164	162	172	178	182	128	80.00	62.00	41.00	45.00	46.00	30.00	31.00	35.00	37.00	42.00
Current Assets	-7.5%	163	176	151	155	157	160	135	144	148	152	95.00	72.00	57.00	36.00	41.00	41.00	29.00	31.00	33.00	27.00	30.00
Cash Equivalents	65.6%	9.00	5.00	7.00	24.00	40.00	33.00	30.00	28.00	27.00	32.00	77.00	57.00	34.00	15.00	19.00	9.00	6.00	3.00	3.00	4.00	-
Net PPE	-5.4%	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	-31.9%	53.00	78.00	1.00	5.00	6.00	7.00	6.00	6.00	7.00	8.00	7.00	6.00	6.00	6.00	5.00	4.00	5.00	5.00	5.00	5.00	5.00
Short Term Borrowings	-32.3%	51.00	75.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	9.8%	164	149	151	150	152	153	153	162	167	170	117	68.00	49.00	28.00	33.00	34.00	16.00	17.00	19.00	22.00	-
Retained Earnings	7.8%	-157	-170	-167	-166	-163	-154	-147	-136	-126	-122	-114	-108	-102	-98.18	-92.61	-89.62	-87.33	-83.65	-81.10	-78.82	-74.75
Additional Paid-In Capital	0.4%	321	320	319	317	314	308	301	299	293	292	230	176	152	126	125	123	103	101	100	100	100
Shares Outstanding	0.1%	40.00	40.00	40.00	40.00	40.00	39.00	39.00	39.00	38.00	38.00	28.00	31.00	28.00	-	-	-	-	-	-	-	-
Minority Interest	-2.9%	-0.93	-0.90	-0.89	-0.82	-0.66	-0.66	-0.66	-0.13	0.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	131	-	-	-	170	-	-	-	-	-	228	-	-	-	61.00	-	-	-	43.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-104.3%	-1,418	-694	-2,634	-5,549	-8,062	-2,241	-8,490	-9,125	-11,122	-6,903	-	-9,149	-	-	-3,682	-1,138	-8,263	-6,152	-2,458	-3,357	-3,629
Share Based Compensation	60.4%	1,367	852	1,820	173	2,548	3,050	1,882	4,029	1,776	-	-	985	-	982	-	411	-	317	-423	319	289
Cashflow From Investing	139.9%	29,997	-75,122	-14,710	-13,203	11,260	1,229	10,363	7,359	-99,248	-99,048	-	-43,311	-	-	10,753	294	-2,405	1,199	10,963	-13,237	4,075
Cashflow From Financing	-133.5%	-25,000	74,548	-	2,430	4,175	4,313	-1.00	2,292	60,572	60,563	-	16,308	-	-	29,032	13,012	13,001	586	1,478	19,979	2,316

ORMP Income Statement

2023-12-31

Consolidated Statements of Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUES	$ 1,340	$ 2,703
RESEARCH AND DEVELOPMENT EXPENSES	(8,971)	(27,639)
SALES AND MARKETING	287	(1,851)
GENERAL AND ADMINISTRATIVE EXPENSES	(8,425)	(13,811)
OPERATING LOSS	(15,769)	(40,598)
INTEREST EXPENSES (note 11b)	(2,037)
FINANCIAL INCOME (EXPENSES), NET (note 11a)	22,894	2,934
INCOME (LOSS) BEFORE TAX EXPENSES	5,088	(37,664)
TAX EXPENSES		(100)
NET LOSS (INCOME)	5,088	(37,764)
COMPANY’S STOCKHOLDERS	5,525	(36,561)
NON-CONTROLLING INTERESTS	(437)	(1,203)
NET INCOME (LOSS)	$ 5,088	$ (37,764)
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 0.14	$ (0.94)
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 0.14	$ (0.94)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	40,315,068	38,997,649
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	40,566,901	38,997,649

ORMP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 9,055	$ 40,464
Short-term deposits	95,279	111,513
Marketable securities		3,743
Investments at fair value	57,713
Prepaid expenses and other current assets	537	1,389
Total current assets	162,584	157,109
LONG-TERM ASSETS:
Long-term deposits	7	7
Investments at fair value	51,035
Marketable securities	1,807
Other non-marketable equity securities	3,524	2,700
Amounts funded in respect of employee rights upon retirement	27	24
Property and equipment, net	873	815
Operating lease right of use assets	694	987
Total long-term assets	57,967	4,533
Total assets	220,551	161,642
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,609	4,158
Short-term borrowings	51,013
Deferred revenues		1,340
Payable to related parties	325	1
Operating lease liabilities	267	247
Total current liabilities	53,214	5,746
LONG-TERM LIABILITIES:
Long-term deferred revenues	4,000	4,000
Employee rights upon retirement	28	21
Provision for uncertain tax position	11	11
Operating lease liabilities	342	647
Other liabilities	63	61
Total long-term liabilities	4,444	4,740
COMMITMENTS
EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS’:
Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2023 and December 31, 2022; 40,338,979 and 39,563,888 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively)	485	476
Additional paid-in capital	320,892	314,417
Accumulated deficit	(157,556)	(163,081)
Total stockholders’ equity	163,821	151,812
Non-controlling interests	(928)	(656)
Total equity	162,893	151,156
Total liabilities and equity	$ 220,551	$ 161,642

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

0

CEO	Mr. Nadav Kidron Esq.
WEBSITE	oramed.com
INDUSTRY	Biotechnology

Oramed Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Oramed Pharmaceuticals Inc? What does ORMP stand for in stocks?

ORMP is the stock ticker symbol of Oramed Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oramed Pharmaceuticals Inc (ORMP)?

As of Thu Apr 18 2024, market cap of Oramed Pharmaceuticals Inc is 89.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORMP stock?

You can check ORMP's fair value in chart for subscribers.

What is the fair value of ORMP stock?

You can check ORMP's fair value in chart for subscribers. The fair value of Oramed Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oramed Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORMP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oramed Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORMP is over valued or under valued. Whether Oramed Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Oramed Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORMP.

What is Oramed Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ORMP's PE ratio (Price to Earnings) is 16.46 and Price to Sales (PS) ratio is 66.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oramed Pharmaceuticals Inc's stock?

In the past 10 years, Oramed Pharmaceuticals Inc has provided -0.162 (multiply by 100 for percentage) rate of return.